Multiple Myeloma
Show Only Open Trials
1.
A Phase II Study of Dexamethasone (Decadron), Clarithromycin (Biaxin), and Pomalidomide (CC-4047) for Subjects with Relapsed or Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
2.
A Phase 1/2 Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Untreated Multiple Myeloma
3.
A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Mutliple Myeloma
4.
An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
5.
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Genentech
- Disease Status and/or Stage: Previously Treated t(4;14)-positive Multiple Myeloma
6.
An Open-Label Phase I Study of BB-10901 (IMGN901, huN901-DM1) in Combination with Lenalidomide and Dexamethasone in Patients with CD56- positive Relapsed or Relapsed/Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: ImmunoGen, Inc.
7.
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Onyx Therapeutics
8.
Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Multiple Myeloma
9.
Phase 1/2 Open-Label Study of the Safety and Efficacy of PD 0332991 In Combination with Bortezomib and Dexamethasone in Patients with Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Pfizer
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
10.
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies
- Study Status: Open to Enrollment
- Sponsor: Calistoga Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Hematological Malignancies
11.
A Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in Patients with Malignances Known to Express NY-ESO-1
- Study Status: Open to Enrollment
- Sponsor: Celldex Therapeutics
- Disease Status and/or Stage: Progressive Disease after therapies with curative potential or approved salvage regimen
